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Abstract: The epithelial-mesenchymal transition (EMT) is an example of cellular plasticity, where
an epithelial cell acquires a mesenchymal-like phenotype that increases its migratory and invasive
properties. Stemness is the ability of stem cells to proliferate in an asymmetric way that allows them
to maintain the reservoir of undifferentiated cells with stem cell identity, but also to produce new
differentiated cells. Initial works revealed that activation of the EMT program in epithelial cells
induces the acquisition of stem cell properties, which in the context of cancer may contribute to the
appearance of tumor initiating cells (TIC). However, a number of groups have recently reported that
mesenchymal-epithelial transition (MET) is required for efficient metastatic colonization and that
EMT may be not necessarily associated with stemness. In this review, we summarize recent findings
that extend our knowledge about the crossroads between EMT and stemness and their relevance
under physiological or pathological conditions.
Keywords: EMT; MET; stem; Transforming Growth Factor-β (TGF-β); Snail; Zeb; Twist; Prrx;
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1. Introduction
Cellular plasticity refers to the ability of cells to reversibly change their phenotype [1]. The
epithelial-mesenchymal transition (EMT) is an example of that. EMT is a process where an epithelial
cell acquires a mesenchymal-like phenotype that increases its migratory and invasive properties. This
phenomenon takes place during both physiological and pathological conditions, particularly during
embryogenesis and cancer [2]. The reverse process of EMT, called mesenchymal-epithelial transition
(MET), occurs several times during embryogenesis [2], allowing cells to settle and differentiate into
different organs and tissues. The hypothesis that mesenchymal migratory tumor cells would need
to undergo MET to metastasize was proposed years ago [3]. However, the full understanding
about how EMT and MET modulate metastasis continues being still matter of interest in different
laboratories nowadays.
Stemness is the ability of stem cells (SC) to proliferate in an asymmetric way that allows them
to serve as a reservoir of cells that maintain stem cell identity, but also as a source of new and more
differentiated cells. Cancer stem cells have been proposed as the driving force of tumorigenesis and
the seed of metastases [4]. Remarkably, activation of the EMT program in non-transformed epithelial
cells confers properties of SC [5], which in the context of cancer would contribute to the appearance
of tumor initiating cells (TIC) [6]. However, a number of groups have recently reported that MET is
required for efficient metastatic colonization of mesenchymal-like migrating cells and that EMT might
be not necessarily associated with stemness [7,8].
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2. Epithelial-Mesenchymal Transition (EMT) and Stemness: General Overview
The EMT process is regulated by numerous signaling pathways that include the Transforming
Growth Factor-β (TGF-β) family (includedins: BMP), fibroblast growth factor (FGF), Notch
and Wnt, among others [9]. hepatocyte growth factor (HGF), interleukin-6 (IL-6) and other
cytokines/chemokines derived from mesenchymal cells may promote de-differentiation, although
their roles in triggering cancer cell EMT are not fully understood yet [9]. TGF-β is one of the strongest
inducers of EMT under both physiological and pathological contexts [10]. It is considered a tumor
suppressor factor in epithelial cells, inhibiting growth and inducing apoptosis. However, in advanced
stages of tumorigenesis, cells acquire the capacity to overcome TGF-β-induced suppressor effects
and respond to it undergoing EMT that facilitates migration and invasion [10]. Furthermore, TGF-β
mediates production of mitogenic growth factors that stimulate tumor proliferation and survival [11].
TGF-β1 overexpression in human cancer correlates with tumor progression, metastasis, angiogenesis
and poor prognostic outcome [12].
TGF-β and other EMT inducing factors activate different signals that finally converge in the
expression of Transcription Factors (TFs) that regulate EMT (families of Snail, Zeb, and Twist, among
others) [13]. EMT-TFs are tightly regulated by microRNA networks and epigenetic programs [13], long
non-coding RNAs [14] or protein stabilization [15]. Loss- or gain-of-function experiments in cell and
animal models revealed the involvement of EMT-TFs in both development and cancer [2,3,16]. Snail
(Snai1 gene), which was proposed as an essential regulator of EMT during embryonic development, is a
strong repressor of transcription of the E-cadherin gene [17,18]. Epithelial cells that ectopically express
Snai1 adopt a fibroblastic-like phenotype and acquire invasive properties [17]. Snail protein is present in
the invasive front of tumors, in which E-cadherin expression has been lost [17]. Its expression in human
tumors inversely correlates with the grade of differentiation and is preferentially located in infiltrating
carcinomas presenting lymph node metastases [19]. Specific silencing of Snai1 in human carcinoma cells
leads to a dramatic reduction of in vivo tumor incidence and growth rate and increases the sensitivity
to chemotherapeutics [20]. In the same line of evidence, suppression of Twist (Twist1 gene) in highly
metastatic mammary carcinoma cells inhibits their ability to move from the mammary gland to the
lung [21]. By the contrary, ectopic expression of Twist1 results in loss of E-cadherin-mediated cell-cell
adhesion and activation of mesenchymal markers, both events contributing to tumor metastasis [21].
In human breast cancers, high levels of Twist correlate with invasive lobular carcinoma, a highly
infiltrating tumor type associated with loss of E-cadherin expression [21]. The later identification
of Zeb1/2 and other basic helix-loop-helix (bHLH) transcription factors as inducers of EMT and
potent repressors of E-cadherin in tumor progression [22] strongly suggested that the same molecules
are used to trigger EMT during embryogenesis and tumorigenesis. The mechanisms underlying
the expression of EMT-TFs in primary lesions remain elusive. Several phenomena associated with
tumor progression (inflammation, metabolic stress, or abnormal activation of signaling pathways,
such as those controlled by TGF-β, Wnt, and Notch, among others) are known to trigger expression of
EMT-TFs [23]. Therefore, these pathways are particularly susceptible to gain-of-function mutations
or constitutive signal activation that would force transition toward a mesenchymal phenotype [24].
Oncogenic events would also contribute to elicit these processes. Using oncogene-driven mouse
mammary tumor models and cell-fate mapping strategies, Trimboli et al., suggested that EMT in breast
cancer would be favored by Myc-initiated events [25]. Whole-genome sequencing has revealed some
oncogenic mutations in EMT-TFs [26], but they are not very frequent.
Remarkably, EMT-TFs display also oncogenic functions within the primary lesion that would
affect tumor development. In this sense, EMT-TFs act as survival factors during development and
tumorigenesis [27]. Slug protects hematopoietic progenitors from apoptosis after DNA damage [28].
Snail arrests cell cycle and confers resistance to pro-apoptotic signals, such as TGF-β, which correlates
with higher levels of the anti-apoptotic Mcl-1 and Bcl-x(L) and lower expression of the pro-apoptotic
Bim and Bmf [29,30]. A number of groups have recently reported an essential role for Twist1 in tumor
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initiation that would be independent of its EMT-inducing activity, but related to its effects on inhibiting
apoptosis [31].
Different groups initially revealed that the EMT process induced by TGF-β in epithelial cells
correlates with the appearance of a less differentiated phenotype [32,33]. Mani et al., later proposed that
activation of the EMT program in non-transformed epithelial cells confers properties of SC [5]. In this
sense, chronic treatment of human fetal hepatocytes with TGF-β induces a mesenchymal phenotype
concomitant with loss in the expression of specific hepatic genes and appearance of SC markers,
reminiscent of progenitor-like cells [34]. This process is reversible, since the mesenchymal stem-like
cells re-differentiate to either hepatocytes or bile duct cells under controlled experimental conditions
that provoke MET and re-expression of liver specific genes [34,35].
EMT may also confer stem-like properties on tumor cells. Morel et al., showed that stem and
tumorigenic characters of the cells were driven by EMT [36], using a mammary tumor progression
model. Using a sensitive method to tag and track pancreatic epithelial cells in a mouse model of
pancreatic cancer, Rhim et al., found that disseminated tumor cells showed a mesenchymal phenotype
and exhibited stem cell properties [37]. This would be consistent with the concept of a circulating
(migratory) cancer stem cell (CSC) and supports the idea of a link between the EMT program and
the stemness phenotype. Classical EMT-TFs, such as Snail/Slug, Twist or Zeb1/2, confer CSC
properties [5,6,38]. TGF-β gives rise to tumor-initiating cells in the context of a cirrhotic liver [39].
Furthermore, TGF-β-induced EMT in liver tumor cells correlates with changes in the expression of
stem markers [34,40,41]. However, the way in which EMT and stemness are connected, as well as its
relevance for the metastatic process, are still controversial issues in tumorigenesis.
3. EMT and Stemness: Coupled, Antagonistic or Independent Processes?
First studies prompted to support the hypothesis that the same players that orchestrate EMT
could be controlling stemness. Among others: (i) an elegant cooperative modulation of gene regulation
by Snail and Slug mediates the acquisition of stem cell characteristics toward resisting radiotherapy- or
chemotherapy-mediated cellular stress [42]; (ii) Bmi1, a polycomb protein that promotes self-renewal
of certain stem-cell populations, is a direct transcriptional target of the EMT inducer, Twist1 [43];
and (iii) Zeb1 links EMT activation and stemness maintenance by suppressing stemness-inhibiting
microRNAs (miRNAs) [6]. Furthermore, different evidences reveal that the tumor suppressor p53
could regulate EMT-associated stem cell properties. Loss of p53 in mammary epithelial cells leads to
lower expression of miR-200c that correlates with an increase in the expression of EMT and stemness
genes [44]. p53 also inhibits the expression of the stem and progenitor-cell-associated protein Nestin,
restricting cellular plasticity and tumorigenesis in liver cancer [45].
Different groups have recently revealed that stemness-related signaling pathways, such as Wnt,
have also been involved in some aspects of the EMT program. The β-catenin/T-cell Factor 4 (TCF4)
complex binds directly to the Zeb1 promoter and activates its transcription [46]. The expression of
stem-related genes could also be provoking the acquisition of an EMT phenotype. In particular, cluster
of differentiation (CD) 44 or CD133 have been involved not only in the acquisition of stem properties,
but also in the switch to a more mesenchymal, migratory phenotype [47,48]. The standard form of
CD44 (CD44s) regulates the TGF-β-mediated mesenchymal phenotype in liver tumor cells [40,47].
Overexpression of CD44 is associated with low expression of E-cadherin, high expression of vimentin,
a high percentage of phospho-Smad2 positive nuclei and poor prognosis in hepatocellular carcinoma
(HCC) patients [47]. A self-enforcing feed-back loop that employs CD44s to activate Zeb1 expression
renders tumor cell stemness independent of external stimuli, since Zeb1 further promotes CD44s
isoform synthesis [49].
However, embryonic stem cells (ESC) are epithelial-like and MET is required for the nuclear
reprogramming of fibroblasts with the Yamanaka factors (Sox2, Klf4, Oct4 and Myc) [50]. Furthermore,
different groups have indicated that EMT can suppress major attributes of human epithelial TIC [51].
Indeed, constitutive overexpression of the transcription factor Snail1 in epithelial/TIC-enriched
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populations addresses a mesenchymal gene program, but suppresses their self-renewal and metastatic
phenotypes. Conversely, knockdown of EMT factors in mesenchymal-like cancer cell subpopulations
induces a gain in epithelial features and properties of TICs [51]. Ocaña et al., demonstrated that loss in
the expression of the homeobox factor Prrx1 (an EMT inducer that confers migratory and invasive
properties) is required for cancer cells to metastasize in vivo. Lower levels of Prrx1 allow cells to revert
to a more epithelial phenotype, concomitantly with the acquisition of stem cell properties [7]. In the
same line of evidence, Tsai et al., proposed that activation of Twist1 is sufficient to promote carcinoma
cells to undergo EMT and disseminate [8]. However, in distant sites, turning off Twist1 is essential
to allow disseminated tumor cells to proliferate and form metastases [8]. Similarly, breast cancer
metastases in an inducible Snai1 expression mouse model are highly dependent on Snai1 expression
only when the expression is transient [52]. Forced, continuous expression of Snai1 led to a decrease in
lung metastasis [52].
Another possibility could be that EMT and stemness are independent processes. As such, Slug
and Sox9 define the stem cell state in normal mammary glands, but whereas Slug is mainly involved
in the induction of EMT, Sox9 is responsible for the entry into the stem cell phenotype [53]. Authors
suggest that the EMT program is important for inducing entrance into the stem state, but it is not
sufficient on its own to induce this change in differentiated luminal cells. Instead, activation of an
additional genetic program, in the present case through expression of Sox9, is required to work in
concert with the EMT program to induce stemness [53]. Additional evidences have suggested that
Slug is required for Sox9 stabilization and both cooperate to promote cancer SC and metastasis [54].
Remarkably, Schmidt et al., have proposed that although a cross-talk between EMT and stemness
exists, their actions are somehow antagonistic and attenuation of the EMT process is required for the
full acquisition of stem cell properties [55]. Indeed, these authors suggested that Twist1 activation may
prime cells for stem-cell-like properties, but these attributes only emerge and stably persist following
Twist1 deactivation. In line with this idea, Stankic et al., have demonstrated that during metastatic
colonization, Id1 expression induces a MET and stem-like phenotype specifically in breast cancer
whose mesenchymal state is dependent on the Id1 target Twist1. In contrast, this does not occur at the
primary site, where this state is controlled by Snai1 [56]. Thus, Twist1-mediated EMT is a prerequisite
for subsequent Id1-induced stemness during metastatic colonization. These results together would
indicate that EMT contributes to the acquisition of stem cell properties, even though turning off key
master regulators of EMT, such as Snail, Twist or Prrx1, is necessary to acquire TIC properties in the





cell properties  [7].  In  the  same  line of  evidence, Tsai  et  al., proposed  that activation of Twist1  is 
sufficient  to promote  carcinoma  cells  to undergo EMT  and disseminate  [8]. However,  in distant   















may prime  cells  for  stem‐cell‐like properties, but  these  attributes only  emerge  and  stably persist 
following Twist1 deactivation. In line with this idea, Stankic et al., have demonstrated that during 
metastatic colonization, Id1 expression induces a MET and stem‐like phenotype specifically in breast 
cancer whose mesenchymal state  is dependent on  the  Id1  target Twist1.  In contrast,  this does not 
occur at the primary site, where this state is controlled by Snai1 [56]. Thus, Twist1‐mediated EMT is 









since  tumor‐derived exosomes up  taken by organ‐specific  cells would prepare  the pre‐metastatic 
niche [57,58]. Macrophage migration inhibitory factor (MIF) is highly expressed in pancreatic ductal 





J. Clin. Med. 2016, 5, 37 5 of 12
Remarkably, the metastatic niche could be formed even before the arrival of the metastatic cells,
since tumor-derived exosomes up taken by organ-specific cells would prepare the pre-metastatic
niche [57,58]. Macrophage migration inhibitory factor (MIF) is highly expressed in pancreatic ductal
adenocarcinomas (PDACs)-derived exosomes and primes the liver for metastasis [57]. Exosome
proteomics reveals distinct integrins expression patterns [58]. The association to a specific organ is
dependent on the integrins expression [58]. This suggests that exosomal integrins could be used to
predict organ-specific metastasis.
4. Epithelial Plasticity: The EMT Transient State
During embryonic development or pathological situations, cells undergo a partial EMT that
concurs with simultaneous expression of both epithelial and mesenchymal genes [1]. A partial EMT
is also activated as a response to injury in the adult organism, such as during renal fibrosis, where
this intermediate phenotype is defined as the final stage [59,60]. In cancer, the transient nature of
EMT allows mesenchymal cancer cells to partially reverse to the epithelial phenotype to colonize
new tissues and organs [7,8,51]. In view of these results, Brabletz [61] has recently postulated two
different scenarios for EMT during metastasis: (i) EMT and stemness are linked processes that lead
to the formation of migratory CSCs, such as those associated to Twist1 that induces both EMT and
stemness properties (although Twist1 down-regulation appears to be required for recovery of some
epithelial characteristics that are necessary for the metastatic process) [8]; and (ii) EMT and stemness
are independent events, even antagonistically regulated, such as those associated with Prxx1 that
confers EMT and migratory properties but suppresses stemness [7]. In this last model, down-regulation
of Prrx1 is required for the acquisition of stem properties and metastatic colonization. Interestingly,
Ombrato and Malanchi have recently suggested that only an early EMT program would correlate
with CSC capability via a gain of epithelial plasticity, whereas an advanced EMT status may lead
to a less flexible mesenchymal phenotype [62]. In this “EMT-gradient” model, the activation of the
EMT program may present different threshold levels that couple or uncouple EMT from stemness
ability (Figure 2). The initial activation of the EMT program would allow epithelial cell to reprogram
its phenotype to acquire both migratory and stem-like features. However, the acquisition of a fully
committed mesenchymal phenotype (such as that one addressed by Prrx1) may represent an alternative
differentiation program in which stem-like features are lost. Microenvironmental signals might instruct
these two possible phenotypes: more mesenchymal during invasion, more epithelial/stem during
metastatic colonization [62]. The partial mesenchymal state found in different carcinomas is under
the control of multiple EMT programs [13] that differ in EMT-TFs usage, epigenetic and metabolic
reprogramming, as well as paracrine and autocrine signals [63]. Jolly et al. [64], by using a theoretical
framework that couples the core EMT and stemness modules, presented OVOL (a transcription factor
that regulates embryogenesis through its involvement in the differentiation of epidermal progenitor
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It is worth mentioning that another consequence of this EMT gradient state could be the differential
expression of stem markers by CSCs, depending on their epithelial-mesenchymal phenotype. During
an intermediate EMT stage, both epithelial and mesenchymal stem genes can be expressed, as it
occurs after treatment of epithelial HCC cells with TGF-β, where a mixed epithelial-mesenchymal
phenotype is acquired [40]. HCC epithelial cells express high levels of EpCAM and CD133, but very
low levels of CD44 and CD90. However, HCC cells that show a mesenchymal phenotype and autocrine
over-activation of the TGF-β pathway do not express EpCAM or CD133, but they express CD44 and
CD90. When epithelial cells respond to TGF-β, the transient EMT state offers the highest variability
in terms of stem gene expression, since cells simultaneously express EpCAM, CD133, CD44 and
CD90 [40] . Further work will be necessary to understand if this transient state that allows expression
of both epithelial and mesenchymal stem genes confers relevant advantages in terms of functional stem
properties. As suggested by Medema, stemness would be also a flexible—rather than fixed-quality of
tumor cells that can be lost and gained [4].
5. EMT and Stemness in the Crossroads of Chemotherapy Resistance
Finally, but not less importantly, we would like to mention that EMT and stemness, each separately
or coordinately, confer resistance to chemotherapy in cancer cells. From first studies about the role
of EMT in tumor cells, it was evidenced that Snail and Slug induce resistance to chemotherapeutic
agents [27] by antagonizing p53-mediated apoptosis [42]. In the same line of evidence, later studies
demonstrated that other factors, such as Notch and Twist, are involved in tumor resistance through its
capacity to induce EMT [65–67]. EMT-inducing transcription factors, such as Twist, Snail and Slug,
up-regulate ATP-binding cassette (ABC) transporter genes [68], although a recent study demonstrates
that the expression of ABC transporters is dispensable for the induction of chemoresistance by Twist
and Snail [69]. Regardless of the specific mechanisms, two recent different works in genetically
engineered mice reveal that although the contribution of EMT process to metastasis might be less than
previously anticipated, it is necessary for the induction of chemoresistance in breast and pancreatic
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Correspondingly, up-regulation of Snail in breast cancer cells led to the acquisition of stem-like
character concomitant with an increase in chemoresistance [75]. Expression of some stem genes, such
as CD133 [76–78] or CD44 [79], confers chemoresistance. Variant CD44 isoforms induce resistance
to therapeutic drugs, which is linked to the activation of the Src-family tyrosine kinase lyn [79] or
Nanog/Stat3 signaling [80], among others [81]. Treatment of HCC epithelial cells with TGF-β does not
only induce EMT, but also is able to up-regulate CD44 [47]. Under these circumstances, CD44 impairs
the HCC cell response to sorafenib-induced apoptosis [40]. Similarly, cancer stem-like spheres induced
from de-differentiated HCC-derived cell lines showed increased expression of stemness markers, such
as CD44, and possessed resistance to anti-cancer drugs [82].
Different groups have reported that the miRNAs play important roles in drug-resistant
mechanisms and are, therefore, considered as targets for cancer therapy [83,84]. In many cases, the
miRNAs are controlling EMT and stemness. As an example, overexpression of miR-124 targets
Prrx1 and radiosensitizes human colorectal cancer cells [85]. In contrast, down-regulation of
miR-223 reverses EMT, decreases migration and invasion of pancreatic cancer cells and sensitizes
them to gemcitabine [86]. The family of miR-200 influences the EMT phenotype by regulating
the expression of Zeb1/2. Its re-expression is expected to induce not only the reversion of EMT,
but also self-differentiation, inhibiting CSC self-renewal capability [84]. Interestingly, miR-200c is
down-regulated in trastuzumab-resistant cells that have undergone EMT and show elevated TGF-β
signaling. Restoration of the miR-200c expression in these cells suppresses TGF-β signaling and its
target Zeb1, counteracting trastuzumab resistance [87]. An innovative approach was used in a study by
Meidhof et al., to identify new strategies to overcome chemoresistance in pancreatic cancer [88]. They
found that downregulation of miR-203 induces Zeb1 activation; therefore, the restoration of miR-203
would induce sensitivity against chemotherapy. Additionally, mocetinostat (an epigenetic drug
that inhibits histone deacetylase activity-HDAC) was identified to interfere with miR203 expression,
restoring sensitivity to chemotherapy [88].
6. Concluding Remarks
The EMT phenotype is an example of cellular plasticity, where different intermediate situations
may occur. This is the reason for so many different, sometimes controversial, findings about the role
of this process in tumor progression. There is no doubt about the essential role of EMT in mediating
cell migration and survival. However, when circulating TICs show a mesenchymal phenotype,
re-acquisition of epithelial features is required for metastasis, a process that converges with gain of cell
tumor initiating capacity. Response of tumor cells to chemotherapeutic agents is somehow dependent
on their mesenchymal-TIC phenotype. Therefore, the analysis of the molecular mechanisms that
regulate all these processes remains being an attractive focus of investigation in the search for new
tools to fight tumor metastasis, which at the end is the major cause of death by cancer.
A clear challenge for the following years will be the development of new animal models for better
understanding the function of EMT-TFs in stemness. Most of the previous studies involved ectopic
expression of EMT-TFs, or their regulatory factors, often at non-physiological levels. Interestingly, the
Weinberg group has recently developed genetically engineered knock-in reporter mouse lines, where
they underscore profound differences in the transcription-regulating activities of the endogenously
encoded Slug and Snail, proving that normal stem cells and TICs of the same tissue-of-origin could
arise from different cellular compartments and exploit different molecular signaling pathways [89].
Indeed, the development of sophisticated fate-mapping experiments in animal models is required to
completely understand the cross-talk between EMT/MET and stemness and its relevance in cancer
progression and metastasis.
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